Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Arsenic Trioxide in Treating Men With Germ Cell Cancer

Study:

Phase II Study Of Arsenic Trioxide In Patients With Refractory Germ Cell Malignancies

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Purpose:

Phase II trial to study the effectiveness of arsenic trioxide in treating men who have germ cell cancer that has not responded to previous treatment.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Extragonadal Germ Cell Tumor
Testicular Germ Cell Tumor
Drug: arsenic trioxide Phase 2

Verified by Southwest Oncology Group August, 2004

Sponsored by: Southwest Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00036842

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195-9001
United States

Tomasz M. Beer, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site